567 related articles for article (PubMed ID: 23033485)
41. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
Bai YL; Liu HB; Sun B; Zhang Y; Li Q; Hu CW; Zhu JX; Gong DM; Teng X; Zhang Q; Yang BF; Dong DL
J Mol Cell Cardiol; 2011 Nov; 51(5):876-80. PubMed ID: 21820442
[TBL] [Abstract][Full Text] [Related]
42. Comparative effects of liensinine and neferine on the human ether-a-go-go-related gene potassium channel and pharmacological activity analysis.
Dong ZX; Zhao X; Gu DF; Shi YQ; Zhang J; Hu XX; Hu MQ; Yang BF; Li BX
Cell Physiol Biochem; 2012; 29(3-4):431-42. PubMed ID: 22508050
[TBL] [Abstract][Full Text] [Related]
43. Propofol inhibits hERG K
Han SN; Jing Y; Yang LL; Zhang Z; Zhang LR
Eur J Pharmacol; 2016 Nov; 791():168-178. PubMed ID: 27575519
[TBL] [Abstract][Full Text] [Related]
44. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
45. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
Qu Y; Fang M; Gao B; Chui RW; Vargas HM
J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
[TBL] [Abstract][Full Text] [Related]
46. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Xia M; Shahane SA; Huang R; Titus SA; Shum E; Zhao Y; Southall N; Zheng W; Witt KL; Tice RR; Austin CP
Toxicol Appl Pharmacol; 2011 May; 252(3):250-8. PubMed ID: 21362439
[TBL] [Abstract][Full Text] [Related]
47. Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.
Kim YJ; Hong HK; Lee HS; Moh SH; Park JC; Jo SH; Choe H
J Cardiovasc Pharmacol; 2008 Dec; 52(6):485-93. PubMed ID: 19034039
[TBL] [Abstract][Full Text] [Related]
48. Understanding of molecular substructures that contribute to hERG K+ channel blockade: synthesis and biological evaluation of E-4031 analogues.
Vilums M; Overman J; Klaasse E; Scheel O; Brussee J; IJzerman AP
ChemMedChem; 2012 Jan; 7(1):107-13. PubMed ID: 21919210
[TBL] [Abstract][Full Text] [Related]
49. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
50. The 5-HT2 antagonist ketanserin is an open channel blocker of human cardiac ether-à-go-go-related gene (hERG) potassium channels.
Tang Q; Li ZQ; Li W; Guo J; Sun HY; Zhang XH; Lau CP; Tse HF; Zhang S; Li GR
Br J Pharmacol; 2008 Oct; 155(3):365-73. PubMed ID: 18574455
[TBL] [Abstract][Full Text] [Related]
51. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
52. HERG K+ channel blockade by the novel antiviral drug sophocarpine.
Zhao XL; Qi ZP; Fang C; Chen MH; Lv YJ; Li BX; Yang BF
Biol Pharm Bull; 2008 Apr; 31(4):627-32. PubMed ID: 18379053
[TBL] [Abstract][Full Text] [Related]
53. Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin.
Choi SW; Kim KS; Shin DH; Yoo HY; Choe H; Ko TH; Youm JB; Kim WK; Zhang YH; Kim SJ
Pflugers Arch; 2013 Aug; 465(8):1121-34. PubMed ID: 23440458
[TBL] [Abstract][Full Text] [Related]
54. [3H]dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel?
Finlayson K; Pennington AJ; Kelly JS
Eur J Pharmacol; 2001 Feb; 412(3):203-12. PubMed ID: 11166283
[TBL] [Abstract][Full Text] [Related]
55. [Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
Zhou SB; Wang J; Liu H
Yao Xue Xue Bao; 2016 Oct; 51(10):1530-9. PubMed ID: 29932317
[TBL] [Abstract][Full Text] [Related]
56. A novel missense mutation causing a G487R substitution in the S2-S3 loop of human ether-à-go-go-related gene channel.
Kinoshita K; Yamaguchi Y; Nishide K; Kimoto K; Nonobe Y; Fujita A; Asano K; Tabata T; Mori H; Inoue H; Hata Y; Fukurotani K; Nishida N
J Cardiovasc Electrophysiol; 2012 Nov; 23(11):1246-53. PubMed ID: 22764740
[TBL] [Abstract][Full Text] [Related]
57. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
58. Recent developments in computational prediction of HERG blockage.
Wang S; Li Y; Xu L; Li D; Hou T
Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
[TBL] [Abstract][Full Text] [Related]
59. Electrophysiological characterization of a small molecule activator on human ether-a-go-go-related gene (hERG) potassium channel.
Dong X; Liu Y; Niu H; Wang G; Dong L; Zou A; Wang K
J Pharmacol Sci; 2019 Jul; 140(3):284-290. PubMed ID: 31481348
[TBL] [Abstract][Full Text] [Related]
60. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
Titus SA; Beacham D; Shahane SA; Southall N; Xia M; Huang R; Hooten E; Zhao Y; Shou L; Austin CP; Zheng W
Anal Biochem; 2009 Nov; 394(1):30-8. PubMed ID: 19583963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
